You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed AML

Showing 26 - 50 of 6,742
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, Relapsed AML, Refractory AML Trial in Hong Kong (NEI-01)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • Hong Kong, Hong Kong
    The University of Hong Kong Phase I Clinical Trials Centre
May 6, 2022

Acute Myeloid Leukemia Trial in Xuzhou (allogenic NK cells)

Recruiting
  • Acute Myeloid Leukemia
  • allogenic NK cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Acute Myeloid Leukemia, Adult, MDS Trial in Marseille, Paris, Pierre-Bénite (ABD-3001)

Active, not recruiting
  • Acute Myeloid Leukemia, Adult
  • Myelodysplastic Syndromes
  • Marseille, France
  • +2 more
Jan 19, 2023

Relapsed Acute Myeloid Leukaemia Trial (Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL))

Not yet recruiting
  • Relapsed Acute Myeloid Leukaemia
  • Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)
  • (no location specified)
Jul 4, 2023

Acute Myeloid Leukemia (AML) Trial in San Francisco (Niclosamide)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • San Francisco, California
    Stanford University
Jun 8, 2022

Relapsed/Refractory Acute Myeloid Leukemia (AML) Trial in Dresden, Heidelberg (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia (AML)
  • Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
  • Gemtuzumab Ozogamicin
  • Dresden, Germany
  • +1 more
Dec 20, 2022

AML, Adult Recurrent, MDS Trial in United States (LYT-200)

Recruiting
  • AML, Adult Recurrent
  • MDS
  • Los Angeles, California
  • +13 more
Apr 12, 2023

Acute Myeloid Leukemia Trial in Baltimore (Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Dose Escalation -tagraxofusp-erzs
  • Dose Expansion at RP2D -tagraxofusp-erzs
  • Baltimore, Maryland
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jan 27, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Granulocytic Sarcoma Trial in Winston-Salem (drug,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • +2 more
  • CPI 613
  • +3 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
May 10, 2023

Relapsed Adult AML Trial in Germany (Venetoclax Oral Tablet)

Recruiting
  • Relapsed Adult AML
  • Refractory AML
  • Venetoclax Oral Tablet
  • Augsburg, Germany
  • +11 more
Jan 11, 2023

AML, MDS Trial in Tianjin (XZB-0004)

Not yet recruiting
  • AML
  • MDS
  • Tianjin, Tianjin, China
    Hematology Hospital, Chinese Academy of Medical Sciences
Feb 13, 2023

Acute Myeloid Leukemia (AML) Trial in Tianjin (Donafenib)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Disease Hospital
Jun 21, 2021

Immunotherapy, Refractory Leukemia, Relapsed Adult AML Trial in Suzhou (Visilizumab)

Recruiting
  • Immunotherapy
  • +3 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 2, 2021

AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)

Not yet recruiting
  • AML, Adult
  • +4 more
  • Amiens, France
  • +19 more
Sep 1, 2023

Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia Trial in Xiamen (venetoclax combining chidamide and

Recruiting
  • Leukemia, Myeloid, Acute
  • +2 more
  • venetoclax combining chidamide and azacitidine (VCA)
  • Xiamen, Fujian, China
    Bing Xu
Aug 1, 2022

Relapsed Acute Myeloid Leukemia Trial in Saint Louis (Flotetuzumab, Donor lymphocyte infusion)

Recruiting
  • Relapsed Acute Myeloid Leukemia
  • Saint Louis, Missouri
    Washington University School of Medicine
Sep 7, 2022

AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

Not yet recruiting
  • AML
  • +11 more
  • (no location specified)
Aug 14, 2023

Acute Myeloid Leukemia Trial (WU-NK-101)

Not yet recruiting
  • Acute Myeloid Leukemia
  • WU-NK-101
  • (no location specified)
Jul 20, 2022

Relapsed Adult AML, Refractory AML Trial in Milwaukee (Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level

Not yet recruiting
  • Relapsed Adult AML
  • Refractory AML
  • Navitoclax Dose Level -1
  • +10 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Aug 17, 2023

Acute Myeloid Leukemia Trial in Hanzhou (Clifutinib Besylate)

Recruiting
  • Acute Myeloid Leukemia
  • Clifutinib Besylate
  • Hanzhou, China
    the First Affiliated Hospital,College of Medicine,Zhejiang Unive
Aug 10, 2022

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti-siglec-6 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti-siglec-6 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Aug 2, 2022

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Trial in China (BL-M11D1)

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
  • Hefei, Anhui, China
  • +7 more
Jun 27, 2023

Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome Trial in Japan, United States (ASP7517)

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome
  • ASP7517
  • Duarte, California
  • +15 more
Jan 19, 2023

Recurrent Acute Myeloid Leukemia Trial in United States (Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine)

Suspended
  • Recurrent Acute Myeloid Leukemia
  • Enasidenib Mesylate
  • Liposome-encapsulated Daunorubicin-Cytarabine
  • Los Angeles, California
  • +3 more
Sep 27, 2022

AML, AML, Adult Trial in Indianapolis (TAK-659, Ixazomib)

Terminated
  • AML
  • AML, Adult
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Cancer Center
Mar 15, 2022